Population genetic structure of variable drug response
暂无分享,去创建一个
David B. Goldstein | Mark G. Thomas | Michael E. Weale | D. Goldstein | M. Weale | Mark George Thomas | N. Bradman | James F. Wilson | Neil Bradman | Alice C. Smith | Fiona Gratrix | Benjamin Fletcher | F. Gratrix | Alice Smith | B. Fletcher | Fiona Gratrix
[1] G. Kearns,et al. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. , 1999, Pharmacogenetics.
[2] D. Labuda,et al. Susceptibility to Childhood Acute Lymphoblastic Leukemia : Influence of CYP 1 A 1 , CYP 2 D 6 , GSTM 1 , and GSTT 1 Genetic Polymorphisms , 1999 .
[3] D. Labuda,et al. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. , 1999, Blood.
[4] J. Goldstein,et al. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. , 1996, Methods in enzymology.
[5] G R Wilkinson,et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. , 1998, The Journal of pharmacology and experimental therapeutics.
[6] F. Rousset,et al. AN EXACT TEST FOR POPULATION DIFFERENTIATION , 1995, Evolution; international journal of organic evolution.
[7] D. Grant,et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[8] M. Relling,et al. Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.
[9] J. Brockmöller,et al. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. , 1999, British journal of clinical pharmacology.
[10] P. Donnelly,et al. Inference of population structure using multilocus genotype data. , 2000, Genetics.
[11] D. Grant,et al. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. , 1998, Pharmacogenetics.
[12] M Masellis,et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia , 2000, Molecular Psychiatry.
[13] D. Goldstein,et al. Consistent long-range linkage disequilibrium generated by admixture in a Bantu-Semitic hybrid population. , 2000, American journal of human genetics.
[14] M. Ingelman-Sundberg,et al. Nomenclature for human CYP2D6 alleles. , 1996, Pharmacogenetics.
[15] Eric Minch,et al. Genetic evidence for a higher female migration rate in humans , 1998, Nature Genetics.
[16] M. Ingelman-Sundberg,et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. , 1999, Pharmacogenetics.
[17] J. S. Miles,et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.
[18] Chikayuki Naito,et al. Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .
[19] U. Meyer,et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.
[20] U. Meyer,et al. Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.